The evolving science around longevity, and its unknowns
Longevity Research Is Getting More Precise, but Its Answers Remain Incomplete
Bharatmorning.com – Ageing is no longer viewed solely as the number of birthdays a person has had. Scientists are increasingly able to examine how different parts of the body are changing over time, and those measurements suggest that ageing is often uneven. A person may have one organ that appears substantially older than the rest of their body, potentially signalling a higher likelihood of disease in that specific system.
Research over the past two decades has identified 12 major processes associated with biological decline. These include DNA damage, changes in the chemical markers that regulate genes, failure of the cell structures responsible for producing energy, and the accumulation of damaged cells that remain alive while promoting inflammation around them.
Blood-based protein analysis has also made it possible to estimate the biological age of individual organs. Certain proteins largely originate in one organ, giving researchers clues about how that organ is functioning. In a study involving nearly 5,700 adults, close to 20% had one organ ageing faster than the others. The organ showing accelerated decline was linked with the condition a person was more likely to face: rapid heart ageing, for example, was associated with heart failure, while faster brain ageing was linked with Alzheimer’s disease.
Drugs Targeting the Biology of Ageing
Once researchers can identify and measure an ageing mechanism, it becomes a potential target for treatment. Several prominent medicines and compounds are being studied for that reason, though none has yet demonstrated in a large clinical trial that it can broadly slow human ageing.
Rapamycin, originally used in transplant medicine, affects a cellular pathway that helps cells decide whether to grow or conserve resources based on nutrient availability. Semaglutide, a GLP-1 medicine used for diabetes and weight management, can reduce inflammation and visceral abdominal fat. Rentosertib is designed to suppress the activity of senescent cells, the damaged cells that persist and may affect nearby tissue. NMN, sold as a supplement, is intended to raise levels of a molecule involved in converting food into cellular energy; that molecule tends to decline with age.
Three of these four interventions were developed for conditions unrelated to longevity. Their possible effects on biological ageing are therefore still an open scientific question rather than an established medical use.
Why Biological Clocks Can Disagree
A September 2026 trial highlighted the challenge of determining whether a treatment is truly altering the pace of ageing. Researchers tested rentosertib in 42 people with a scarring lung disease, for which the drug had been developed. Participants receiving the highest daily dose showed a reduction of roughly three years in predicted age after four weeks.
That result depended on ageing clocks: computer models trained on blood data from thousands of people. Such models examine a new sample and generate an age-related score. Yet the significance of that score depends heavily on what the model was trained to measure.
Some clocks are designed simply to estimate chronological age. A lower result in those models indicates that a blood sample resembles one from a younger individual. Other clocks focus on illness risk or premature death. They are trained using blood patterns seen in people who remained healthier for longer, making their results potentially more relevant to future health outcomes.
In the rentosertib study, four age-estimating clocks suggested that participants appeared about three years younger. Two risk-focused clocks, however, did not show a meaningful shift. The participants’ blood may have looked younger by one measure without appearing less vulnerable to disease by another. The study authors also noted that they could not clearly distinguish a general slowing of ageing from improvement in the lung condition being treated.
A Yale review published in August 2026 examined 16 clocks across 51 studies of interventions intended to slow ageing. It found that risk clocks responded consistently to genuine physical changes, while conventional age clocks did not move in a reliably consistent pattern.
The clocks are misleading unless they are deployed in the context of a specific physiological condition. If all clocks show different time, then the clocks are wrong, not the time,
Deepak Kumar Saini, a professor at the Indian Institute of Science and coordinator of BHARAT, an Indian study of human ageing, argues that a clock reading has value only when it is connected to the particular biological condition being assessed.
Older Habits Still Have the Strongest Support
The interventions with evidence from longer trials are neither experimental nor expensive. Studies lasting two to three years in healthy older adults have found clock-related improvements from shingles vaccination, omega-3 plus vitamin D, exercise and daily multivitamin use. The changes were measured in months rather than years, but they offer a reminder that practical health measures remain important while longevity science develops.
Newer treatments can also involve meaningful risks. Rapamycin suppresses immune activity in order to protect transplanted organs. Using it off label in a healthy person could make infections easier to establish. This concern is especially significant in India, where tuberculosis and other infections are more prevalent than in many Western countries where interest in rapamycin as an anti-ageing option grew. Reducing immune defences in healthy adults may increase their exposure to infection.
A Map for Better Prevention
For the moment, one of the most useful outcomes of longevity research may be better identification of vulnerable organs rather than a single medicine that promises extra years. If one organ appears to be ageing faster than the rest of the body, that information may justify closer monitoring through the established medical tests used to identify disease in that organ.
Biological age measurements should therefore be treated as clues, not verdicts. They may help doctors and patients focus prevention efforts, but they do not yet provide a universal answer to how long someone will live or whether a treatment has truly slowed ageing across the whole body.
Related Reading
Frequently Asked Questions
What is The evolving science around longevity and its?The evolving science around longevity and its is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does The evolving science around longevity and its matter?The evolving science around longevity and its matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.